Search results for "Ovarian Cancer"

showing 10 items of 206 documents

Prognostic factors of overall survival for patients with FIGO stage IIIc or IVa ovarian cancer treated with neo-adjuvant chemotherapy followed by int…

2020

International audience; Introduction The aim of this study was to identify prognostic factors of overall survival in patients with FIGO stage IIIc or IVa ovarian cancer (OC) treated by neo-adjuvant chemotherapy (NAC) followed by interval debulking surgery.Materials and methods Data from 483 patients with ovarian cancer were retrospectively collected, from January 1, 2000 to December 31, 2016, from the FRANCOGYN database, regrouping data from 11 centers specialized in ovarian cancer treatment. Median overall survival was determined using the Kaplan-Meier method. Univariate and multivariate analysis were performed to define prognostic factors of overall survival.Results The median overall sur…

Neoplasm Residualmedicine.medical_treatmentGenes BRCA2FIGO Stage IIICGenes BRCA1Platinum CompoundsCarcinoma Ovarian EpithelialCohort Studies0302 clinical medicineAscitic FluidOverall survivalPeritoneal Lavage030212 general & internal medicineOvarian NeoplasmsUnivariate analysisCytoreduction Surgical ProceduresGeneral MedicineMiddle AgedPrognosisDebulkingNeoadjuvant Therapy3. Good healthSurvival RateOncology030220 oncology & carcinogenesisFemaleTaxoidsFranceOmentumCohort studymedicine.medical_specialty[SDV.CAN]Life Sciences [q-bio]/CancerAntineoplastic Agents[SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetricsInterval debulking surgeryNeoadjuvant chemotherapyPelvis03 medical and health sciences[SDV.CAN] Life Sciences [q-bio]/CancerOvarian cancerMedian follow-upmedicineHumansNeoplasm InvasivenessAgedNeoplasm StagingProportional Hazards Modelsbusiness.industryRetrospective cohort studymedicine.diseaseSurgery[SDV.MHEP.GEO] Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieMultivariate AnalysisLymph Node Excision[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieSurgeryLymphadenectomyLymph NodesOvarian cancerbusinessEuropean Journal of Surgical Oncology
researchProduct

Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trial–NCT02324595): a feasibility study

2016

Background Laparoscopy has acquired an increasing role in the management of ovarian cancer. Laparoscopic cytoreduction could represent a new frontier for selected patients after neoadjuvant chemotherapy (NACT). Objective We sought to assess feasibility and early complication rate of minimally invasive (MI) interval debulking surgery (IDS) in stage III-IV epithelial ovarian cancer (EOC) patients after NACT. Study Design This is a phase II multicentric study in advanced EOC cases with clinical complete response after NACT, according to Gynecologic Cancer Intergroup and Response Evaluation Criteria In Solid Tumors criteria. Institutional review board approval was obtained and all patients sign…

Neoplasm Residualmedicine.medical_treatmentchemotherapyresidual0302 clinical medicine80 and overMedicineminimally invasive surgeryAged 80 and overOvarian Neoplasms030219 obstetrics & reproductive medicineadvanced ovarian cancerMedicine (all)Obstetrics and GynecologyCytoreduction Surgical ProceduresBowel resectionMiddle AgedDebulkinglaparoscopic cytoreductionNeoadjuvant TherapyIntestinesChemotherapy AdjuvantResponse Evaluation Criteria in Solid Tumors030220 oncology & carcinogenesisinterval debulking surgeryFemaleMedian bodyPeritoneumOmentumneoadjuvant chemotherapyAdultmedicine.medical_specialtyOvariectomyadvanced ovarian cancer; interval debulking surgery; laparoscopic cytoreduction; minimally invasive surgery; neoadjuvant chemotherapy; quality of life; Adult; Aged; Aged 80 and over; Appendectomy; Chemotherapy Adjuvant; Fallopian Tubes; Feasibility Studies; Female; Humans; Hysterectomy; Intestines; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence Local; Neoplasm Residual; Omentum; Ovarian Neoplasms; Ovariectomy; Peritoneum; Cytoreduction Surgical Procedures; Laparoscopy; Medicine (all); Obstetrics and GynecologyHysterectomy03 medical and health sciencesadjuvantlocalAppendectomyHumansSurvival rateFallopian TubesAgedHysterectomybusiness.industryAdvanced ovarian cancer interval debulking surgery laparoscopic cytoreduction minimally invasive surgery neoadjuvant chemotherapy quality of life adult aged 80 and over appendectomy chemotherapy adjuvant fallopian tubes feasibility studies female humans hysterectomy intestines middle aged neoadjuvant therapy neoplasm recurrence local neoplasm residual omentum ovarian neoplasms ovariectomy peritoneum cytoreduction surgical procedures laparoscopyPerioperativeneoplasm recurrenceSurgerySettore MED/40 - GINECOLOGIA E OSTETRICIAquality of lifeFeasibility StudiesLaparoscopyLymphadenectomyNeoplasm Recurrence LocalbusinessneoplasmAmerican Journal of Obstetrics and Gynecology
researchProduct

Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: a case series.

2014

Objective To analyze the feasibility of laparoscopic/robotic secondary cytoreductive surgery and hyperthermic intraperitoneal intra-operative chemotherapy (SCS + HIPEC) in a retrospective series of isolated platinum sensitive recurrent ovarian cancer. Methods We retrospectively evaluated a consecutive series of ovarian cancer patients with isolated platinum sensitive relapse. Isolated relapse was defined as the presence of a single nodule, in a single anatomic site. In all cases the presence of isolated relapse was assessed at pre-operative FDG-PET/CT scan, and confirmed with staging laparoscopy performed immediately before SCS + HIPEC. Results 84 women with platinum sensitive relapse recei…

OVARIAN CANEROrganoplatinum Compoundsmedicine.medical_treatmentdrug therapy/pathology/surgery/therapyCarcinoma Ovarian EpithelialMultimodal ImagingCohort StudiesObstetrics and gynaecologyNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsInfusions ParenteralNeoplasms Glandular and EpithelialLaparoscopyadministration /&/ dosageTomographyRandomized Controlled Trials as TopicOvarian Neoplasmsmedicine.diagnostic_testObstetrics and GynecologyGlandular and EpithelialMiddle AgedDebulkingCombined Modality TherapyIsolated platinum sensitive relapseX-Ray ComputedOxaliplatinPhase III as TopicOncologyFemalediagnostic usemedicine.drugmedicine.medical_specialtyInfusionsAged Antineoplastic Combined Chemotherapy Protocols; administration /&/ dosage Cisplatin; administration /&/ dosage Clinical Trials; Phase II as Topic Clinical Trials; Phase III as Topic Cohort Studies Combined Modality Therapy Female Fluorodeoxyglucose F18; diagnostic use Humans Hyperthermia; Induced; methods Infusions; Parenteral Middle Aged Minimally Invasive Surgical Procedures Multimodal Imaging Neoplasms; Glandular and Epithelial; drug therapy/pathology/surgery/therapy Organoplatinum Compounds; administration /&/ dosage Ovarian Neoplasms; drug therapy/pathology/surgery/therapy Positron-Emission Tomography Radiopharmaceuticals; diagnostic use Randomized Controlled Trials as Topic Retrospective Studies Tomography; X-Ray Computed ocal; pathologyocalmethodsClinical Trials Phase II as TopicMinimally invasive surgeryOvarian cancerFluorodeoxyglucose F18ParenteralmedicineHumansMinimally Invasive Surgical ProceduresClinical TrialsHyperthermiaAgedRetrospective StudiesCisplatinChemotherapySeries (stratigraphy)HIPECbusiness.industryPhase II as TopicInducedHyperthermia Inducedmedicine.diseaseOxaliplatinSurgeryRoboticSettore MED/40 - GINECOLOGIA E OSTETRICIAClinical Trials Phase III as TopicPositron-Emission TomographyLaparoscopypathologyNeoplasm Recurrence LocalCisplatinRadiopharmaceuticalsbusinessOvarian cancerTomography X-Ray Computed
researchProduct

Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MIT…

2011

Purpose Carboplatin/paclitaxel is the standard first-line chemotherapy for patients with advanced ovarian cancer. Multicentre Italian Trials in Ovarian Cancer-2 (MITO-2), an academic multicenter phase III trial, tested whether carboplatin/pegylated liposomal doxorubicin (PLD) was more effective than standard chemotherapy. Patients and Methods Chemotherapy-naive patients with stage IC to IV ovarian cancer (age ≤ 75 years; Eastern Cooperative Oncology Group performance status ≤ 2) were randomly assigned to carboplatin area under the curve (AUC) 5 plus paclitaxel 175 mg/m2 or to carboplatin AUC 5 plus PLD 30 mg/m2, every 3 weeks for six cycles. Primary end point was progression-free survival (…

OncologyAdultCancer Researchmedicine.medical_specialtySettore MED/06 - Oncologia Medicamedicine.medical_treatmentAntineoplastic AgentsPolyethylene GlycolDisease-Free Survivallaw.inventionCarboplatinPolyethylene GlycolsAntineoplastic Agentchemistry.chemical_compoundRandomized controlled triallawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansDoxorubicinAgedOvarian NeoplasmsChemotherapyAntineoplastic Combined Chemotherapy Protocolbusiness.industryOvarian NeoplasmArea under the curveCancerMiddle Agedmedicine.diseaseCarboplatinSurgerySettore MED/40 - GINECOLOGIA E OSTETRICIAOncologychemistryPaclitaxelDoxorubicinQuality of LifeFemalebusinessOvarian cancerHumanmedicine.drug
researchProduct

Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicente…

2006

Abstract Background Carboplatin/paclitaxel is the chemotherapy of choice for advanced ovarian cancer, both in first line and in platinum-sensitive recurrence. Although a significant proportion of patients have some neurotoxicity during treatment, the long-term outcome of chemotherapy-induced neuropathy has been scantly studied. We retrospectively assessed the prevalence of residual neuropathy in a cohort of patients in clinical remission after first-line carboplatin/paclitaxel for advanced ovarian cancer. Methods 120 patients have been included in this study (101 participating in a multicentre phase III trial evaluating the efficacy of consolidation treatment with topotecan, and 19 treated …

OncologyAdultmedicine.medical_specialtyCancer ResearchTime Factorsendocrine system diseasesPaclitaxelmedicine.medical_treatmentlcsh:RC254-282Severity of Illness IndexCarboplatinchemistry.chemical_compoundMedian follow-upInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineGeneticsHumansAgedRetrospective StudiesOvarian NeoplasmsChemotherapybusiness.industryCancerPeripheral Nervous System DiseasesRetrospective cohort studyMiddle Agedmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCarboplatinfemale genital diseases and pregnancy complicationsClinical trialchemistryOncologyTopotecanFemalebusinessOvarian cancerTopotecanmedicine.drugResearch Article
researchProduct

Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma.

2010

Abstract Objective The excision repair cross-complementation group 1 (ERCC1) expression is a predictor of survival after surgical treatment for several malignancies. Its overexpression has been reported as a marker of platinum resistance in lung cancer. However, the relevance of ERCC1 expression in ovarian cancer (OC) is the subject of controversy, both as a predictive parameter for platinum resistance and because of its association with poor prognosis. Therefore, we performed a retrospective study investigating ERCC1 expression and its correlation with patients' survival in OC. Methods We analyzed the ERCC1 protein expression using four different ERCC1 antibodies (clone 8F1) with different…

OncologyAdultmedicine.medical_specialtyNeoplasm Residualmedicine.medical_treatmentERCC1 Protein ExpressionPredictive Value of TestsInternal medicineOvarian carcinomamedicineHumansLung cancerSurvival rateAgedNeoplasm StagingRetrospective StudiesAged 80 and overOvarian NeoplasmsChemotherapybusiness.industryAge FactorsObstetrics and GynecologyMiddle Agedmedicine.diseaseEndonucleasesImmunohistochemistryCystadenocarcinoma SerousDNA-Binding ProteinsSerous fluidOncologyFemaleERCC1businessOvarian cancerGynecologic oncology
researchProduct

79 VUS VARIANTS IN BRCA GENES OF HEREDITARY BREAST/OVARIAN CANCER

2010

OncologyBreast ovarian cancermedicine.medical_specialtyOncologybusiness.industryInternal medicinemedicineRadiology Nuclear Medicine and imagingGeneral MedicinebusinessBrca genesCancer Treatment Reviews
researchProduct

Celecoxib plus carboplatin in heavily pre-treated patients with recurrent ovarian carcinoma: preliminary results of a Phase II study

2005

5060 Background: Cyclooxygenase-2 (COX-2) expression is associated with a poor chance of response to chemotherapy and poor prognosis in ovarian cancer (OC). Celecoxib, an orally active COX-2 inhibi...

OncologyCancer ResearchPoor prognosisChemotherapymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentPhases of clinical researchmedicine.diseaseCarboplatinchemistry.chemical_compoundOrally activeOncologychemistryInternal medicinemedicineCelecoxibOvarian cancerbusinessRecurrent Ovarian Carcinomamedicine.drugJournal of Clinical Oncology
researchProduct

Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers

2011

[Background]: Germline mutations in the BRCA1 and BRCA2 genes are associated with increased risks of breast and ovarian cancers. Although several common variants have been associated with breast cancer susceptibility in mutation carriers, none have been associated with ovarian cancer susceptibility. A genome-wide association study recently identified an association between the rare allele of the single-nucleotide polymorphism (SNP) rs3814113 (ie, the C allele) at 9p22.2 and decreased risk of ovarian cancer for women in the general population. We evaluated the association of this SNP with ovarian cancer risk among BRCA1 or BRCA2 mutation carriers by use of data from the Consortium of Investi…

OncologyCancer Researchendocrine system diseasesGenes BRCA2Genes BRCA1Genome-wide association studyFAMILIES0302 clinical medicineRisk FactorsRetrospective StudieGenotypeOdds Ratioskin and connective tissue diseasesPOPULATIONGeneticsOvarian NeoplasmsAged 80 and overAllele0303 health scienceseducation.field_of_studyLikelihood FunctionsArticlesGERMLINE MUTATIONSMiddle AgedLikelihood Functionfemale genital diseases and pregnancy complications3. Good healthOncology030220 oncology & carcinogenesisFemaleChromosomes Human Pair 9HumanAdult[SDV.OT]Life Sciences [q-bio]/Other [q-bio.OT]medicine.medical_specialtyHeterozygoteSUSCEPTIBILITY LOCIGenotypePROTEINSPopulationBiologyPolymorphism Single NucleotideBASONUCLIN-203 medical and health sciencesBreast cancerGermline mutationSDG 3 - Good Health and Well-beingInternal medicinemedicineBREAST-CANCERHumansGENOME-WIDE ASSOCIATIONeducationAllelesGerm-Line Mutation030304 developmental biologyRetrospective StudiesAgedIDENTIFICATIONRisk FactorOvarian NeoplasmEditorialsCancermedicine.diseaseMinor allele frequencyOvarian cancer
researchProduct

Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: prelimi…

2006

Abstract Background The MITO-2 (Multicentre Italian Trials in Ovarian cancer) study is a randomized phase III trial comparing carboplatin plus paclitaxel to carboplatin plus pegylated liposomal doxorubicin in first-line chemotherapy of patients with ovarian cancer. Due to the paucity of published phase I data on the 3-weekly experimental schedule used, an early safety analysis was planned. Methods Patients with ovarian cancer (stage Ic-IV), aged 2, every 3 weeks or to carboplatin AUC 5 plus pegylated liposomal doxorubicin 30 mg/m2, every 3 weeks. Treatment was planned for 6 cycles. Toxicity was coded according to the NCI-CTC version 2.0. Results The pre-planned safety analysis was performed…

OncologyCancer Researchendocrine system diseasesSettore MED/06 - Oncologia Medicamedicine.medical_treatmentPACLITAXELlaw.inventionPolyethylene Glycolschemistry.chemical_compoundRandomized controlled trialSTAGE-IIIlawCYCLOPHOSPHAMIDEAntineoplastic Combined Chemotherapy ProtocolsOvarian NeoplasmsSTERICALLY STABILIZED LIPOSOMESMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCombined Modality Therapyfemale genital diseases and pregnancy complicationsPaclitaxelOncologyMITO-2 randomized trialcarboplatinSURVIVALFemaleChemical and Drug Induced Liver Injurymedicine.drugAgranulocytosisResearch ArticleAdultmedicine.medical_specialtyCARCINOMAOvariectomylcsh:RC254-282Drug Administration ScheduleDrug HypersensitivityCISPLATINpreliminary resultInternal medicinemedicineGeneticsXENOGRAFTSHumansDoxorubicinParesthesianeoplasmsMETAANALYSISAgedChemotherapybusiness.industryAlopeciamedicine.diseasePHASE-IIIThrombocytopeniaCarboplatinSurgeryClinical trialchemistryDoxorubicinLiposomesFeasibility StudiesTopotecanOvarian cancerbusinessBMC Cancer
researchProduct